SSA
BMRN icon

Schonfeld Strategic Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-32,400
Closed -$5.9K – 1798
2023
Q2 		$5.9K Buy
+32,400
New +$3.05M ﹤0.01% 1938

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schonfeld Strategic Advisors's BMRN Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 257,419 shares — an estimated $15.3M sold.

Schonfeld Strategic Advisors first reported a position in BMRN in Q2 2016 and held it in 28 quarters. The position peaked at $25.7M in Q3 2025. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 257,419 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $15.3M.
  • Schonfeld Strategic Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2016 and held it in 28 quarters.
  • Schonfeld Strategic Advisors's BioMarin Pharmaceuticals position peaked at $25.7M in Q3 2025.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.